AHA Statement Redefines Exercise Prescription for High-Risk Cardiac Patients

Exercise is widely recognized as one of the most powerful interventions for cardiovascular disease, yet many of the highest-risk patients are largely left out of existing programs. A new scientific statement from the American Heart Association directly addresses this gap, offering clinicians detailed guidance on exercise training for populations that standard cardiac rehabilitation protocols often fail to reach.

The statement covers seven high-risk groups: individuals with frailty, stroke survivors, those with spinal cord injuries, patients with rheumatological conditions, individuals with genetic cardiomyopathies, recipients of advanced heart failure therapies such as left ventricular assist devices and heart transplants, and patients with cardiac implantable electronic devices such as pacemakers and defibrillators. Each group faces a distinct combination of physical limitations, safety considerations, and barriers to participation that require individualized approaches.

Four key findings cut across all these populations. First, barriers to exercise participation are elevated at multiple levels — patient, provider, and health system. Second, baseline cardiorespiratory fitness is markedly low in these groups, underscoring how urgently they need structured exercise. Third, exercise prescriptions must go beyond standard aerobic training to incorporate strength, balance, and flexibility work, often with enhanced supervision and adaptive equipment. Fourth, and most encouragingly, well-designed programs produce functional and quality-of-life improvements that are at least as large as those seen in more typical cardiac patients.

For clinicians, this statement provides a framework to move beyond 'this patient is too complex for rehab' thinking. The evidence suggests that with appropriate modifications, even the most fragile or medically complex patients can benefit meaningfully from structured exercise.

Important caveats apply. The statement is based on a review of existing literature, and knowledge gaps remain significant across all covered populations. Future randomized trials with patient-centered outcomes are needed, as is work on how to deliver these programs equitably and at scale.